Multiplikator Forward P/S scpharmaceuticals.com (SCPH)
scPharmaceuticals Inc. complies with basic environmental standards by outsourcing pump production to external partners. The projected price-to-sales ratio visualizes market expectations, where 6.00 shows the current value of the metric. scPharmaceuticals Inc. is implementing the Furoscix system for home treatment of heart failure, reducing hospital expenses. Its status as an innovator and the trust of cardiologists confirm the high value of the therapy for patients.
Rincian metrik lan analitis perusahaan scpharmaceuticals.com (SCPH)
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal scPharmaceuticals Inc.|SCPH - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas scPharmaceuticals|SCPH - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku scPharmaceuticals Inc.|SCPH - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan scPharmaceuticals|Rasio cepet scpharmaceuticals.com
- data bathi bisnis lan rasio investasi:
SCPH - Penghasilan resik|Proyeksi bathi mangsa ngarep scPharmaceuticals Inc.|SCPH - Kapitalisasi marang bathi|Prakiraan rega marang bathi scPharmaceuticals|SCPH - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan scPharmaceuticals Inc.|SCPH - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) scPharmaceuticals|SCPH - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan scpharmaceuticals.com|SCPH - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep scPharmaceuticals Inc.
- informasi babagan volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:SCPH (scPharma)
This indicator compares the current market capitalization of scPharmaceuticals Inc. (SCPH) with projected revenue to determine the premium for future growth and the potential acquisition value of the asset. Amid the expansion of the home heart failure treatment segment, the estimated forward P/S reflects how the market values the effectiveness of reducing hospitalization costs, allowing investors to identify business undervaluation or operational risks.
Pesaing scPharmaceuticals Inc. (SCPH)
Rasio rega marang prakiraan pendapatan Haleon HLN|Rasio kapitalisasi marang dodolan sing dikarepake Kenvue Inc (KVUE)|Verona Pharma Corp - Multiplikator Forward P/S|Jyong Bio (MENS) - Multiplikator forward rega marang pendapatan|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan AMRX (amneal.com)|PRGO (Perrigo) - Multiplikator Forward P/S|ALVO: Rega forward marang dodolan|Multiplikator Forward P/S LQDA|Multiplikator Forward P/S Galapagos Corp (GLPG)|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|Rega forward marang dodolan MNKD|AMPH - Rasio rega marang prakiraan pendapatan|Pacira Pharmaceuticals (PCRX) - Multiplikator forward rega marang pendapatan|SPRY: Multiplikator Forward P/S|Theravance Corp (TBPH) - Multiplikator Forward P/S|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Tectonic (TECX)|Multiplikator Forward P/S TNXP|SXTC - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Eupraxia Pharmaceuticals Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S BioHarvest Sciences Inc BHST|EXOZ: Multiplikator forward rega marang pendapatan|Oramed Pharmaceuticals - Rasio rega marang pendapatan sing dikarepake|ENTX: Multiplikator Forward P/S|HYFT - Rasio kapitalisasi marang dodolan sing dikarepake|ABVC (ABVC BioPharma Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cumberland Corp (CPIX)|Multiplikator Forward P/S QNTM|Multiplikator Forward P/S fibrogen.com (FGEN)|Rasio rega marang prakiraan pendapatan Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings - Rasio rega marang prakiraan pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Rallybio Corporation RLYB|LEXX (lexariabioscience.com) - Multiplikator forward rega marang pendapatan|pulmatrix.com - Rega forward marang dodolan|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|Aptorum (APM) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Multiplikator forward rega marang pendapatan|PRFX: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Altamira Therapeutics CYTO|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|OPTN - Rasio kapitalisasi marang dodolan sing dikarepake|PIRS (Pieris Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan procapsgroup.com (PROC)|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Rega forward marang dodolan TFFP
